输血依赖患者的合免疫率和相关因素:来自沙特阿拉伯的区域研究
Clinical laboratory
|January 16, 2026
概括
在Aseer研究中,同免疫影响了10.2%的输血依赖患者,与Rh-D阳性和高输血量有关. 扩展表型化等策略可以降低这种风险.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 输血医学 输血医学
背景情况:
- 输血至关重要,但存在风险,包括因重复暴露而导致的免疫.
- 同免疫接种,即对外来红细胞产生抗体,在对输血依赖患者的治疗中构成了重大挑战.
- 了解与免疫接种相关的患病率和风险因素对于患者安全和有效的输血策略至关重要.
研究的目的:
- 确定阿塞尔省在输血依赖患者中与免疫接种的患病率.
- 在这个患者队列中确定与非免疫接种相关的关键风险因素.
- 为制定有针对性的干预措施提供信息,以减轻免疫风险.
主要方法:
- 对149名输血依赖患者的医疗记录进行了回顾性分析.
- 收集的数据包括患者的人口统计,诊断,血型,Rh型表型和输血史.
- 评估了alloantibodies的患病率和与临床因素的关联.
主要成果:
- 同免疫接种的总体患病率为10.2% (149名患者中15名).
- 在血型O和Rh-D阳性状态的患者中,合免疫接种更为常见.
- 显著的危险因素包括年龄,Rh-D阳性和每年接受超过15个输血单位.
结论:
- 输血依赖的患者,特别是具有Rh-D阳性和高输血负担的患者,面临着与免疫接种相关的高风险.
- 实施扩展的红细胞表型和匹配的输血协议可以帮助最大限度地减少与免疫接种.
- 优化输血政策对于减少这一群体免疫复杂症至关重要.
相关概念视频
Blood Transfusion and Agglutination
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
The ABO Blood Group
The ABO blood group system is a critical element of transfusion medicine, essential for determining blood compatibility in transfusions and organ transplants. It is based on specific antigens, or agglutinogens, present on the surface of red blood cells (RBCs) and corresponding antibodies, or agglutinins, in the blood plasma.
Antigens in the ABO Blood Group System
Antigens are substances that can trigger an immune response, leading to the production of antibodies. In the ABO blood group system,...
Antigens in the ABO Blood Group System
Antigens are substances that can trigger an immune response, leading to the production of antibodies. In the ABO blood group system,...
Rh Blood Group
The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
Blood Transfusion
Blood transfusion is a critical medical procedure that saves lives and treats various medical conditions. It involves transferring blood from a donor to a recipient. This process requires a thorough understanding of the ABO blood group system and its associated antigens and antibodies.
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...

